Support for projects of the Brazilian government, the national health system and UNICEF
Submitted by Bayer
Bayer will donate EUR 1 million (R$ 5.7 million) to help combat the coronavirus pandemic in Brazil.
Approximately EUR 490,000 (R$ 2.8 million) is being contributed to the Brazilian government’s “Solidaric Fundraising” campaign to finance various projects for the prevention, diagnosis and treatment of COVID-19. Around EUR 350,000 (R$ 2 million) will go to UNICEF in Brazil to support children, youth projects and underprivileged communities. Another approximately EUR 160,000 (R$ 900,000) will enable the national health system to purchase face masks, protective gear and equipment for hospitals.
“The crisis caused by the COVID-19 pandemic challenges all of us. The collaboration between the public and private sectors and civil society will be crucial to overcome these challenges,” said Marc Reichardt, Senior Bayer Representative in Brazil. “Our contribution goes far beyond financial support. Our employees are working around the clock to maintain the availability of medicines and food in Brazil.”
Bayer is supporting the worldwide fight against the corona pandemic with its products, technical equipment, know-how and the engagement of its employees. You can find a current overview here: https://www.bayer.com/en/coronavirus-covid-19-update.aspx.
A digital press kit is available at: https://www.media.bayer.com/baynews/baynews.nsf/id/presskit-corona
More information about the “All united against the virus” alliance can be found at: https://www.fondationdefrance.org/fr/tous-unis-contre-le-virus-la-fondation-de-france-lap-hp-et-linstitut-pasteur-lancent-un-appel-la
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
Follow us on Twitter: twitter.com/Bayer
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
More from Bayer